
What is claimed is

1. Pharmacologically σ active catechol derivatives of formula I



I

wherein R₁ and R₂ independently comprise hydrogen, alkyl, optionally substituted acyl, optionally substituted aroyl, lower alkylsulfonyl or alkylcarbamoyl or taken together form a lower alkylidene or cycloalkylidene group, X comprises electronegative substituent such as halogen, nitro, cyano, lower alkylsulfonyl, sulfonamido, trifluoromethyl, aldehyde or carboxyl and R₂ comprises hydrogen, halogen, substituted alkyl, hydroxyalkyl, nitro, cyano, optionally substituted amino, trifluoromethyl, lower alkylsulfonyl, sulfonamide, aldehyde, alkylcarboxyl, aralkylidenecarboxyl or carboxyl group or a group selected from

-CH-C-R₅, or -CH₂-CH-R₅

wherein R_4 comprises hydrogen, alkyl, amino, cyano, carboxyl or acyl and R_5 comprises hydrogen, amino, cyano, carboxyl, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, hydroxyalkyl, carboxyalkyl, COZ, wherein Z is an optionally substituted heterocyclic ring or one of following optionally substituted groups; carboxamido, carbamoyl, aroyl or heteroaryl or R_4 and R_5 together form a five to seven membered substituted cycloalkanone ring;

$$-(co)_n(ch_2)_m-cor$$

wherein n is 0-1, m is 0-7 and R comprises alkyl, hydroxy,

60

carboxyalkyl, optionally substituted alkene, optionally substituted heterocyclic ring, alkoxy or substituted amino;

wherein R₈ and R₉ independently comprise hydrogen or one of the following optionally substituted groups; alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl or taken together form an optionally substituted piperidyl group;


wherein R₁₀ comprises a substituted alkyl group.

- 2. A compound as claimed in claim 1, wherein the compound is $3,4-dihydroxy/5-nitro-\omega,\omega-dicyanostyrene$.
- 3. A compound as claimed in claim 1, wherein the compound is 4-(3,4-dihydroxy-5-nitrophenyl)-3-methylbut-3-en-2-one.
- 4. A compound as claimed in claim 1, wherein the compound is 3-(3,4-dihydroxy-5-nitrophenyl)-1-(3,4,5-trimethoxyphenyl)-prop-2-en-1-pne.
- 5. A compound as claimed in claim 1, wherein the compound is 3-(3,4-dihydroxy-5-nitrophenyl)-1-phenylprop-2-en-1-one.
- 6. A compound as claimed in claim 1, wherein the compound is N-methyl-N-propargyl-5-(3,4-dihydroxy-5-nitrophenyl)pentanoic acid amide.
- 7. A compound as claimed in claim 1, wherein the compound is 4-(3,4-dihydroxy-5-nitrophenyl)-3-methylbut-3-en-2-ol.
- 8. A compound as claimed in claim 1, wherein the compound is N-(1-adamantyl)-5-(3,4-dihydroxy-5-nitrophenyl)pentanoic acid amide.

- 9. A compound as claimed in claim 1, wherein the compound is N-isopropyl-5-(3,4-dihydroxy-5-nitrophenyl)pentanoic acid amide.
- 10. A compound as claimed in claim 1, wherein the compound is 4-hydroxy-3-methoxy-5-nitrocinnamic acid.
- 11. A compound as claimed in claim 1, wherein the compound is 5-(3,4-dihydroxy-5-nitrophenyl)pentanoic acid.
- 12. A compound as claimed in claim 1, wherein the compound is 2,5-bis-(3,4-dihydroxy-5-nitrobenzylidene)cyclopentanone.
- 13. A compound as claimed in claim 1, wherein the compound is 2-propionylexy-6-nitrophenol.
- 14. A compound as claimed in claim 1, wherein the compound is 1,2-diacetoxy-3,5-dinitrobenzene.
- 15. A compound as claimed in claim 1, wherein the compound is 3',4'-dihydroxy-5'-nitroacetophenone.
- 16. A compound as claimed in claim 1, wherein the compound is 3,4-dihydroxy-5-nitrobenzaldehyde.
- 17. A compound as claimed in claim 1, wherein the compound is 3,4-dihydroxy-5-nitrobenzonitrile.
- 18. A compound as claimed in claim 1, wherein the compound is 4-chloro-6-nitrocatechol.
- 19. A compound as claimed in claim 1, wherein the compound is 1,2-dipropionyloxy-3,5-dinitrobenzene.
- 20. A compound as claimed in claim 1, wherein the compound is 2-pivaloyloxy-4,6-dinitrophenol.

21. A compound as claimed in claim 1, wherein ythe compound is 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione.

22. A method for the preparation of new pharmacologically active catechol derivatives of the formula



I

wherein R₁ and R₂ independently comprise hydrogen, alkyl, optionally substituted acyl, optionally substituted aroyl, lower alkylsulfonyl or alkylcarbamoyl or taken together form a lower alkylidene or cycloalkylidene group, X comprises electronegative substituent such as halogen, nitro, cyano, lower alkylsulfonyl, sulfonamido, trifluoromethyl, aldehyde or carboxyl and R₃ comprises hydrogen, halogen, substituted alkyl, hydroxyalkyl, nitro, cyano, optionally substituted amino, trifluoromethyl, lower alkylsulfonyl, sulfonamide, aldehyde, alkylcarbonyl, aralkylidenecarbonyl or carboxyl group or a group selected from

wherein R₄ comprises hydrogen, alkyl, amino, cyano, carboxyl or acyl and R₅ comprises hydrogen, amino, cyano, carboxyl, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, hydroxyalkyl, carboxyalkyl, COZ, wherein Z is an optionally substituted heterocyclic ring or one of following optionally substituted groups; carboxamido, carbamoyl, aroyl or heteroaryl or R₄ and R₅ together form a five to seven membered substituted cycloalkanone ring;

$$-(co)_n(cH_2)_m$$
-cor

wherein n is 0-1, m is 0-7 and R comprises alkyl, hydroxy,

carboxyalkyl, optionally substituted alkene, optionally substituted heterocyclic ring, alkoxy or substituted amino;

wherein R₈ and R₉ independently comprise hydrogen or one of the following optionally substituted groups; alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl or taken together form an optionally substituted piperidyl group;

wherein R₁₀ comprises a substituted alkyl group, wherein the method comprises an acid or base catalyzed condensation reaction of a compound of formula II




wherein R_1 , R_2 and X are as defined above, with a compound of formula III

having an active methylor methylene group and wherein R_4 and R_5 are as defined above to give the compounds of formula Ia

$$R_1O$$
 R_2O
 $CH=C$
 R_5


wherein the substituents are as defined above and wherefrom the double bond optionally may be reduced to a single bond;

or a ketone of formula IV




IV

wherein R_1 , R_0 and X are as defined above and R_6 is hydrogen or alkyl, is dondensed with an aldehyde of formula V



V

wherein R₇ comprises hydrogen, alkyl, alkoxy or dialkylamino to give compounds of formula Ib




Ιb

wherein R_1 , R_2 , X, R_6 and R_7 are as defined above; or a compound of formula VI

VI

wherein R_1 and R_2 are as defined above is allowed to react with a cyclic acid anhydride of formula VII



VII

wherein m is 1-7 or with a dicarboxylic acid ester chloride of formula VIII


 $Hal_{(CO)_n-(CH_2)_mCOR}$

VIII

wherein m is 0-7 and n is 0-1 and R is as defined above and Hal is a halogen atom to give the compounds of formula IX

$$R_1^0$$
 — $CO)_n(CH_2)_mCOR$ IX

wherein the aromatic ring will be substituted with the group X to give compounds of formula Ic



which compound may be reduced to give compounds of formula Id;

 R_1^{0} CH_2^{0} CH_2^{0} CH_2^{0} CH_2^{0} CH_2^{0}

or by allowing a compound of formula X



wherein R_1 and R_2 are as defined above and Y comprises halogen or another activated group to react with an amine of formula XI

R₈ XI

wherein R_8 and R_9 are as defined above to give compounds of formula Ie

$$R_1^0$$
 R_2^0 R_9 R_9

wherein R_1 , R_2 , X, R_8 and R_9 are as defined above; or by allowing the aniline derivative of formula XII

wherein R₁, R₂ and X are as defined above, to react with an activated carboxylic acid derivative of formula XIII,

wherein Y and R_{10} are as defined above to give compounds of formula If

$$R_{2}^{0}$$
 NH-CO- R_{10}

wherein the substituents are as defined above; or by allowing the compound of formula II

wherein \mathbf{R}_1 and \mathbf{R}_2 are as defined above and X comprises a halogen atom to react with cuprous cyanide in a polar,

aprotic solvent at elevated temperature or optionally by formylating 2,3-dihydroxybenzonitrile with hexamethylene tetramine to give compounds of formula II, wherein X comprises a cyano group;

or by allowing a compound of formula XIV



to react sequentially with butyllithium, trimethylborate and peroxyformic acid to give the compound of formula XV

CH₃
HO-CF₃

which compound may be formylated with hexamethylenetetramine in fluoroacetic acid to give a compound of formula XVI

which compound may be demethylated to the compound of formula XVII;

or by treating the compound of formula XVIII

IIIVX

CH₃O

with peroxyacetic acid to give the sulfone compound of formula XIX

CH₃O XIX

which compound is formylated to give the compound of formula xx

СH₃О СНО СНО SO₂ СН₃

which compound may be demethylated to give the corresponding hydroxy compound of formula XXI;

HO CHO
SO₂
CH₃

or by formylation the compound of formula XXII

HO HO R11

XXII

wherein R₁₁ comprises hydrogen or alkyl, to the compound of formula XXIII

HO CHO
SO₂N
R₁₁

XXIII.

- 23. A method as claimed in claim 21, wherein the compounds of the formula VI and the formula VIII are allowed to react in the presence of aluminium chloride.
- 24. A method as claimed in claim 21, wherein the compound of the formula Ic is reduced to a compound of the formula Id by Clemmensen or Wolff-Mischner reduction.
- 25. A composition in a pharmaceutically acceptable form comprising the compound as claimed in claim 1 as an active ingredient.
- 26. A composition as claimed in claim 24, comprising the compound as claimed in claim 1, levodopa and optionally a periferic decarboxylase inhibitor.
- 27. A composition as claimed in claim 24, wherein the periferic decarboxylase inhibitor is carbidopa.
- 28. A composition as claimed in claim 24, wherein the periferic decarboxylase inhibitor is benzerazide.

add add